INBX
Inhibrx Biosciences, Inc. · Healthcare · Market cap $1.4B
Insiders bought $6.1M net in the last 90 days ·1 seller, 3 buyers· latest Form 4 filed Oct 14, 2026
Insider Buying
$6.3M
reported purchases (SEC code P)
Insider Selling
$279K
reported sales (SEC code S)
Unique Insiders
4
in the rolling window
Latest filing
Oct 14, 2026
Lappe Mark
Inhibrx Biosciences, Inc. (INBX) has 9 SEC Form 4 filings (25 transaction rows) in the rolling window, disclosed by 4 distinct insiders. Most recent filing: Oct 14, 2026.
Inside the rolling window, 4 insiders at Inhibrx Biosciences, Inc. reported 8 open-market purchases totaling $6.3M and 5 open-market sales totaling $279K. The most active filer is Director MANHARD KIMBERLY with 5 filings. Insiders have net bought $6.1M over the trailing 6 months. The largest single insider purchase in this window was $2.6M by Chief Executive Officer Lappe Mark on Sep 8, 2026. The most recent open-market filing is a purchase of 9,940 shares by Chief Executive Officer Lappe Mark, dated Oct 14, 2026, worth $840K.
- Industry:Biotechnology
- CEO:Mark Lappe
- Employees:110
- HQ:La Jolla, CA, US
- IPO:2024-05-29
| Source | |||||||
|---|---|---|---|---|---|---|---|
| Chief Executive Officer | Purchase | 9,940 | $840K | Oct 14 | cluster+15.2% | SEC ↗ | |
| Chief Executive Officer | Purchase | 5,500 | $545K | Sep 28 | cluster-3.5% | SEC ↗ | |
| Chief Executive Officer | Purchase | 4,500 | $453K | Sep 28 | cluster-3.5% | SEC ↗ | |
| Director | Purchase | 5,000 | $500K | Sep 23 | — | SEC ↗ | |
| Director | Purchase | 5,000 | $500K | Sep 17 | — | SEC ↗ | |
| Director | Sale | 500 | $56K | Sep 15 | — | SEC ↗ | |
| Director | Sale | 500 | $55K | Sep 15 | — | SEC ↗ | |
| Director | Sale | 500 | $53K | Sep 15 | — | SEC ↗ | |
MANHARD KIMBERLYFirst filing | Director | Sale | 500 | $58K | Sep 10 | — | SEC ↗ |
MANHARD KIMBERLYFirst filing | Director | Sale | 500 | $58K | Sep 10 | — | SEC ↗ |
Kayyem Jon FaizFirst filing | Director | Purchase | 5,000 | $568K | Sep 8 | — | SEC ↗ |
Lappe MarkFirst filing | Chief Executive Officer | Purchase | 25,000 | $2.6M | Sep 8 | — | SEC ↗ |
FORSYTH DOUGLASFirst filing | Director | Purchase | 2,500 | $287K | Sep 8 | — | SEC ↗ |
Frequently asked questions
How many SEC Form 4 insider filings does INBX have?
Inhibrx Biosciences, Inc. (INBX) has 9 SEC Form 4 filings (25 transaction rows) in the rolling 365-day window, disclosed by 4 distinct insiders. Most recent filing: Oct 14, 2026.
When was the most recent SEC Form 4 filing for INBX?
The most recent Form 4 filing for INBX on Tracefour is dated Oct 14, 2026.
Who is the most active insider at INBX?
The most active SEC Form 4 filer at INBX in the rolling window is Director MANHARD KIMBERLY, with 5 filings.
What is the net insider flow at INBX over the last 6 months?
Over the trailing 180 days, insiders at INBX have net bought $6.1M based on SEC Form 4 disclosures.
What was the largest insider purchase at INBX?
The largest single insider open-market purchase at INBX in the rolling window was $2.6M by Chief Executive Officer Lappe Mark on 2026-09-08.
What is the total insider buy and sell value at INBX in the current window?
Inside the rolling window, insiders at INBX bought $6.3M and sold $279K based on SEC Form 4 filings.
Can I get alerts for INBX insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Inhibrx Biosciences, Inc. (INBX). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Inhibrx Biosciences, Inc. is in the Healthcare sector.